|
CalciMedica Appoints Steven L. Schoenfeld, MD, as Vice President, Clinical Development
June 23, 2010
CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition
Patent Involving STIM1, a Key Component of the CRAC Channel
February 16, 2010
CalciMedica Achieves Milestone and Draws Down Second Tranche of $12 Million Series C Financing
December 15, 2009
CalciMedica Appoints Evelyn Graham to its Board of Directors
October 13, 2009
CalciMedica Exercises Option to Acquire Additional Intellectual Property from TorreyPines Therapeutics
October 13, 2008
CalciMedica Acquires Exclusive Rights to Novel Immune Signaling Targets for Treating Autoimmune Diseases from The CBR Institute
May 7, 2007
TorreyPines Therapeutics Transfers Intellectual Property and Compounds for Treating Autoimmune Diseases to CalciMedica
May 7, 2007
|